{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T12:05:58Z","timestamp":1780747558846,"version":"3.54.1"},"reference-count":6,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008087","name":"Guthy-Jackson Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.msard.2016.09.002","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T15:51:46Z","timestamp":1473436306000},"page":"63-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: A case report"],"prefix":"10.1016","volume":"10","author":[{"given":"Lea M.","family":"Gerischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Janke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard Jan","family":"Jungehuelsing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Ruprecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2016.09.002_bib1","first-page":"15","article-title":"Management of thrombotic thrombocytopenic purpura: current perspectives","volume":"5","author":"Blombery","year":"2014","journal-title":"J. Blood Med."},{"key":"10.1016\/j.msard.2016.09.002_bib2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1212\/WNL.0b013e3181aaea1b","article-title":"Brain lesions are most often reversible in acute thrombotic thrombocytopenic purpura","volume":"73","author":"Burrus","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2016.09.002_bib3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing-remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.msard.2016.09.002_bib4","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMc1316118","article-title":"Thrombotic microangiopathy associated with interferon beta","volume":"370","author":"Hunt","year":"2014","journal-title":"N Engl. J. Med."},{"key":"10.1016\/j.msard.2016.09.002_bib5","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1177\/1352458514523692","article-title":"Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in relapsing-remitting multiple sclerosis patients on high-dose interferon beta","volume":"20","author":"Larochelle","year":"2014","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2016.09.002_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.msard.2013.12.007","article-title":"Thrombotic microangiopathy in interferon beta treated multiple sclerosis patients: review of literature and report of two new cases","volume":"3","author":"Vosoughi","year":"2014","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103481630164X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103481630164X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:40:42Z","timestamp":1761900042000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103481630164X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":6,"alternative-id":["S221103481630164X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2016.09.002","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: A case report","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2016.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}